My Companies
Notification
Account
Log Out
Login
Natco received US FDA tentative approval for Olaparib tablets (100mg, 150mg), a generic of Lynparza, with estimated US sales of $1.4B. Partner Alembic will distribute. Para IV litigation is ongoing.
Natco Pharma Sets ₹1,279 Crore Rights Issue At ₹750 Per Share
Natco Pharma Fixes ₹750 Price For ₹1,279 Crore 2:21 Rights Issue
Natco Pharma Proposes ₹1,300 Crore Rights Issue For Debt Repayment
Natco Pharma Approves Rights Issue Of Up To ₹1,300 Crore
Natco Pharma Explores ₹2,000 Crore Capital Raise Alongside Q1 Results